Colin G. Buss

Colin G. Buss, PhD

(he/him/his)
Patent Agent | Biotechnology
617.646.8159 Colin.Buss@WolfGreenfield.com LinkedIn Profile

Education

  • Cornell University, BS, Chemical Engineering, cum laude
  • Massachusetts Institute of Technology & Harvard Medical School, PhD, Medical Engineering & Medical Physics
  • Fordham University School of Law, JD, 2025 Candidate

Key Technologies

  • Oligonucleotides
  • Antibodies
  • Antibody-drug Conjugates
  • Nucleic Acid Sequencing 
  • Gene Therapies
  • Nanoparticles
  • Immunotherapies 
  • CRISPR/Cas

Practice Groups

Admitted to Practice

  • US Patent and Trademark Office

Location

  • New York

Overview

Colin Buss assists the firm in patent matters related to biotechnology. He works with a range of clients, including small and large biotechnology companies and universities. His experience includes patent application drafting and prosecution, patentability studies, freedom-to-operate analyses, third-party IP assessment (including diligences, risk assessment, and validity analyses), and general IP strategy. 

Colin has extensive knowledge and experience in the areas of immune cell profiling, immunotherapies, nanoparticle synthesis and characterization, primary cell isolation and culture, oligonucleotide technologies (e.g., antisense technologies, RNAi, and splicing modulation), antibodies and antibody-drug conjugates, synthetic biology, various animal models, and more.

Prior to joining Wolf Greenfield, Colin received his PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences & Technology program. His doctoral research related to nanotechnologies for use in the treatment and diagnosis of various diseases with immunological involvement. His work focused particularly on developing and adapting nanoparticle technologies for the diagnosis, treatment and monitoring of disease, with applications in lung infections and various types of cancer, and included extensive work in cancer immunotherapy. He is also co­inventor of patent applications related to his doctoral thesis work.


Experience

  • Prepared and assisted in prosecution of US and foreign patent applications relating to a range of technologies in the biotechnology space
  • Assisted in the management of global patent portfolios, including those covering clinical stage therapeutics and diagnostics
  • Conducted patentability and freedom-to-operate searches and analyses
  • Analyzed third-party IP for risk assessment and validity
  • Prepared third-party submissions and oppositions in pending patent applications and issued patents

Activities

  • Biomedical Engineering Society
  • American Institute of Chemical Engineers

Recognition

  • NSF Graduate Research Fellowship, National Science Foundation

Publications

  • CG Buss, Bhatia, SN. “Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.” PNAS 117(24):13428-13436 (2020). Doi: 10.1073/pnas.2001569117
  • CG Buss† , Dudani, JS†, Akana, RTK, Fleming, HE, Bhatia, SN. “Protease activity sensors noninvasively classify bacterial infections and antibiotic responses.” EBioMedicine 38: 248-256 (2018). doi:10.1016/j.ebiom.2018.11.031
  • SR Viswanathan, Nogueira, MF†, Buss, CG†, Krill-Burger, JM, Wawer, MJ, Malolepsza, E, Berger, AC, Choi, PS, Shih, J, Taylor, AM, Tanenbaum, B, Pedamallu, CS, Cherniack, AD, Tamayo, P, Strathdee, CA, Lage, K,Carr, SA, Schenone, M, Bhatia, SN, Vazquez, F, Tsherniak, A, Hahn, WC, Meyerson, M, “Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer.” Nature Genetics 50(7):937-943 (2018). doi:10.1038/s41588-018-0155-3
  • JS Dudani, Buss, CG, Akana, RTK, Kwong, GA, Bhatia, SN, “Sustained‐Release Synthetic Biomarkers for Monitoring Thrombosis and Inflammation Using Point‐of‐Care Compatible Readouts.” Advanced Functional Materials 26(17): 2919-2928 (2016). doi:10.1002/adfm.201505142
  • H Goodarzi, Zhang, S, Buss, CG, Fish, L, Tavazoie, S, Tavazoie, SF, “Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins”, Nature 513: 256-260 (2014).doi:10.1038/nature13466
  • N Pencheva†, Buss, CG†, Posada, J, Merghoub, T, Tavazoie, SF, “Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation.” Cell 156(5): 986-1001 (2014).doi:10.1016/j.cell.2014.01.038
  • N Pencheva, Tran, H†, Buss, CG†, Huh, D, Drobnjak, M, Busam, K, Tavazoie, SF, “Convergent multi-miRNA Targeting of ApoE Drives LRP1/LRP8-Dependent Melanoma Metastasis and Angiogenesis.” Cell 151(5): 1068-1082 (2012).doi:10.1016/j.cell.2012.10.028

Interests

Colin is an active runner, amateur photographer, and aspiring chef.